Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

Item

http://www.wikidata.org/entity/Q37118666

Q37118666

about

Mechanisms of Candida biofilm drug resistance Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents Comparison of echinocandin antifungals Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata Epidemiology of invasive candidiasis: a persistent public health problem Stimulation of chitin synthesis rescues Candida albicans from echinocandins.Oropharyngeal candidiasis in the era of antiretroviral therapy Novel FKS mutations associated with echinocandin resistance in Candida species.Peptide-based Antifungal Therapies against Emerging Infections.In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species.Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.Breakthrough invasive candidiasis in patients on micafungin.Regulatory circuitry governing fungal development, drug resistance, and disease.Canadian clinical practice guidelines for invasive candidiasis in adults.Biochemical characterization of an anti-Candida factor produced by Enterococcus faecalis Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptibility Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy.FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study.Effect of the crude extract of Eugenia uniflora in morphogenesis and secretion of hydrolytic enzymes in Candida albicans from the oral cavity of kidney transplant recipients Anidulafungin: an echinocandin antifungal.A Novel Small Molecule Inhibitor of Candida albicans Biofilm Formation, Filamentation and Virulence with Low Potential for the Development of Resistance.Anidulafungin: review of a new echinocandin antifungal agent.Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature Epidemiology and antifungal resistance in invasive candidiasis.Evolution of antifungal-drug resistance: mechanisms and pathogen fitness.Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin.Echinocandins: role in antifungal therapy, 2005.In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.Echinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis.The safety of anidulafungin.The echinocandins.Detection of caspofungin resistance in Candida spp. by Etest.The pharmacology and clinical use of caspofungin.The use of caspofungin in HIV-infected individuals.

P2860

Q26827521-8E8AA19F-74EA-4AE9-A511-3E9398B5DEC3 Q26863344-B02DEA8D-03F4-440F-8FBE-366FE9AE320C Q28273738-C0BC6277-26A6-4C6F-9EFC-68885D68E33F Q28483785-0D906719-4EC6-4E6B-9F8B-3FAAB0BF3C31 Q29616758-4F574B4C-B82B-4D62-BCB2-0C538C5BA45F Q33326983-2B02CC5A-BC0B-4C63-8945-1D6B26CEF0C1 Q33746435-15C85E53-2A0B-4258-8031-329688527AC9 Q33826330-FDF72004-61CB-4720-9EA2-61E3C13D3EF5 Q33862289-6E37767E-DB72-4F6E-9DE9-E2CD72E46F7C Q33876423-02712708-3310-4068-A1B1-03F3F0A4712F Q33935389-325E4A98-9EDC-4E0D-BBE7-64CD65CE324B Q33938068-63E6D913-8B0A-41FC-A490-EC2FF192CD3F Q33963538-E6104D2C-C93F-41E8-8131-4645112F7E1D Q34190284-8982FA91-5C0E-48C5-87A7-FE9B5B7509B1 Q34237335-BE0EA60E-AA81-4D11-95A9-A4760CD332D2 Q34325020-F18BAE19-95DB-46F3-B8CF-0848305AFC94 Q34510707-27026616-25A8-4B2A-9616-9A2D00F45F8B Q34721774-5AEA8133-8D1F-44CD-8D91-887D64BAEB2B Q34737334-1390F5E0-F6C6-4E3F-A1E2-48A7B0D90AEB Q34933267-6BEE06B0-B2EF-4B52-A2BC-0D2D2F87C9D6 Q35073614-5392FB22-7E34-4E50-921F-5D65847F2593 Q35177179-79256BCB-4D46-4DFB-ADF7-E84534BCDF19 Q35555192-8C0CF77D-BCBB-4E8B-903B-11602D59677B Q35871936-2621D3C7-1E53-407E-A873-EEC636440A64 Q35874892-E6815743-F574-47C0-BDE8-CC1463A10588 Q35917456-BAC216DD-A910-47E7-B13C-A3D7A28D1CBB Q35959484-B85760BD-D626-4914-91D4-4AAF23D4AA82 Q35959495-041412D2-CB6E-43F9-8072-8DFDE5C91DF5 Q36161987-051003FF-3DA7-4AF1-977A-9DFEE72E0FD3 Q36176371-F5BAC411-B8C8-4D2E-A175-3C7C4566AE77 Q36222035-67C13045-7F58-48E7-BB9B-10BD8D834B6B Q36425025-936B7B38-C0B1-4A11-AE4A-863AC9327A47 Q36441524-F0B8BDE5-AB7E-4F6B-8358-AAC8CFF43ACF Q36458402-CAB027B4-42A4-4DF5-B4B8-1F87F05307EF Q36505494-B9DDB0EE-1479-49DE-9805-D954242FF8F2 Q36624970-4C7257C7-7DD9-47C7-95A2-59F9242968A7 Q36742397-F7A2F4E8-3E6E-4899-BAF6-5D8B589AADB4 Q36747567-6C9AC36F-A3A1-49FC-B55F-DA596E819E83 Q36788428-85A6095F-CE27-4740-915E-03BBA0EEF4B0 Q36821383-3888BD3E-B9FB-4B14-AC67-CDE71CFD19C4

P2860

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

Item

http://www.wikidata.org/entity/Q37118666

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2004

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Caspofungin resistance in Cand ...... rogressive Candida esophagitis

@en

Caspofungin resistance in Cand ...... ogressive Candida esophagitis.

@nl

type

Item

label

Caspofungin resistance in Cand ...... rogressive Candida esophagitis

@en

Caspofungin resistance in Cand ...... ogressive Candida esophagitis.

@nl

prefLabel

Caspofungin resistance in Cand ...... rogressive Candida esophagitis

@en

Caspofungin resistance in Cand ...... ogressive Candida esophagitis.

@nl

P1476

Caspofungin resistance in Cand ...... rogressive Candida esophagitis

@en

P2093

Dora I McCarthy

http://www.w3.org/2001/XMLSchema#string

John R Graybill

http://www.w3.org/2001/XMLSchema#string

José L López-Ribot

http://www.w3.org/2001/XMLSchema#string

Laura K Najvar

http://www.w3.org/2001/XMLSchema#string

Rosie Bocanegra

http://www.w3.org/2001/XMLSchema#string

Steve Hernandez

http://www.w3.org/2001/XMLSchema#string

P2860

Distinct patterns of gene expression associated with development of fluconazole resistance in serial candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis.

Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans

Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases.

Resistance of Candida species to fluconazole

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients.

Fluconazole resistance in Candida glabrata

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

Compounds active against cell walls of medically important fungi

P304

1382-1383

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.48.4.1382-1383.2004

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2004-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15047549

http://www.w3.org/2001/XMLSchema#string

P921

patient

P932

375251

http://www.w3.org/2001/XMLSchema#string

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

about

P2860

P2860

Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P932